A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings
Michael C Sneller, C Jason Liang, Adriana R Marques, Joyce Y Chung, Sujata M Shanbhag, Joseph R Fontana, Haniya Raza, Onyi Okeke, Robin L Dewar, Bryan P Higgins, Katie Tolstenko, Richard W Kwan, Kathleen R Gittens, Catherine A Seamon, Genevieve McCormack, Jacob S Shaw, Grace M Okpali, Melissa Law, Krittin Trihemasava, Brooke D Kennedy, Victoria Shi, J Shawn Justement, Clarisa M Buckner, Jana Blazkova, Susan Moir, Tae-Wook Chun, H Clifford Lane, Michael C Sneller, C Jason Liang, Adriana R Marques, Joyce Y Chung, Sujata M Shanbhag, Joseph R Fontana, Haniya Raza, Onyi Okeke, Robin L Dewar, Bryan P Higgins, Katie Tolstenko, Richard W Kwan, Kathleen R Gittens, Catherine A Seamon, Genevieve McCormack, Jacob S Shaw, Grace M Okpali, Melissa Law, Krittin Trihemasava, Brooke D Kennedy, Victoria Shi, J Shawn Justement, Clarisa M Buckner, Jana Blazkova, Susan Moir, Tae-Wook Chun, H Clifford Lane
Abstract
Background: A substantial proportion of persons who develop COVID-19 report persistent symptoms after acute illness. Various pathophysiologic mechanisms have been implicated in the pathogenesis of postacute sequelae of SARS-CoV-2 infection (PASC).
Objective: To characterize medical sequelae and persistent symptoms after recovery from COVID-19 in a cohort of disease survivors and controls.
Design: Cohort study. (ClinicalTrials.gov: NCT04411147).
Setting: National Institutes of Health Clinical Center, Bethesda, Maryland.
Participants: Self-referred adults with laboratory-documented SARS-CoV-2 infection who were at least 6 weeks from symptom onset were enrolled regardless of presence of PASC. A control group comprised persons with no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, recruited regardless of their current health status. Both groups were enrolled over the same period and from the same geographic area.
Measurements: All participants had the same evaluations regardless of presence of symptoms, including physical examination, laboratory tests and questionnaires, cognitive function testing, and cardiopulmonary evaluation. A subset also underwent exploratory immunologic and virologic evaluations.
Results: 189 persons with laboratory-documented COVID-19 (12% of whom were hospitalized during acute illness) and 120 antibody-negative control participants were enrolled. At enrollment, symptoms consistent with PASC were reported by 55% of the COVID-19 cohort and 13% of control participants. Increased risk for PASC was noted in women and those with a history of anxiety disorder. Participants with findings meeting the definition of PASC reported lower quality of life on standardized testing. Abnormal findings on physical examination and diagnostic testing were uncommon. Neutralizing antibody levels to spike protein were negative in 27% of the unvaccinated COVID-19 cohort and none of the vaccinated COVID-19 cohort. Exploratory studies found no evidence of persistent viral infection, autoimmunity, or abnormal immune activation in participants with PASC.
Limitations: Most participants with COVID-19 had mild to moderate acute illness that did not require hospitalization. The prevalence of reported PASC was likely overestimated in this cohort because persons with PASC may have been more motivated to enroll. The study did not capture PASC that resolved before enrollment.
Conclusion: A high burden of persistent symptoms was observed in persons after COVID-19. Extensive diagnostic evaluation revealed no specific cause of reported symptoms in most cases. Antibody levels were highly variable after COVID-19.
Primary funding source: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Conflict of interest statement
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-4905.
Figures
References
- World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 87. 12 April 2022.
- Nalbandian A,Sehgal K,Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-15. [PMID: ] doi:10.1038/s41591-021-01283-z
- Blomberg B,Mohn KG,Brokstad KA, et al; Bergen COVID-19 Research Group. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607-13. [PMID: ] doi:10.1038/s41591-021-01433-3
- Logue JK,Franko NM,McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4:e210830. [PMID: ] doi:10.1001/jamanetworkopen.2021.0830
- Menges D,Ballouz T,Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS One. 2021;16:e0254523. [PMID: ] doi:10.1371/journal.pone.0254523
- Taquet M,Dercon Q,Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. [PMID: ] doi:10.1371/journal.pmed.1003773
- Townsend L,Dyer AH,Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784. [PMID: ] doi:10.1371/journal.pone.0240784
- Al-Aly Z,Xie Y,Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259-64. [PMID: ] doi:10.1038/s41586-021-03553-9
- Carfì A,Bernabei R,Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-5. [PMID: ] doi:10.1001/jama.2020.12603
- Hopkins C,Surda P,Whitehead E, et al. Early recovery following new onset anosmia during the COVID-19 pandemic—an observational cohort study. J Otolaryngol Head Neck Surg. 2020;49:26. [PMID: ] doi:10.1186/s40463-020-00423-8
- Tenforde MW,Kim SS,Lindsell CJ, et al; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993-8. [PMID: ] doi:10.15585/mmwr.mm6930e1
- Gershon RC,Cella D,Fox NA, et al. Assessment of neurological and behavioural function: the NIH Toolbox [Letter]. Lancet Neurol. 2010;9:138-9. [PMID: ] doi:10.1016/S1474-4422(09)70335-7
- Scoggins JF,Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from . Contemp Clin Trials. 2009;30:289-92. [PMID: ] doi:10.1016/j.cct.2009.02.005
- Ware JE Jr. Using generic measures of functional health and well-being to increase understanding of disease burden [Editorial]. Spine (Phila Pa 1976). 2000;25:1467. [PMID: ]
- Kroenke K,Spitzer RL,Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50:613-21. [PMID: ] doi:10.1176/appi.psy.50.6.613
- Löwe B,Wahl I,Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86-95. [PMID: ] doi:10.1016/j.jad.2009.06.019
- Tan CW,Chia WN,Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073-8. [PMID: ] doi:10.1038/s41587-020-0631-z
- Huang L,Yao Q,Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747-58. [PMID: ] doi:10.1016/S0140-6736(21)01755-4
- Peluso MJ,Lu S,Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839-48. [PMID: ] doi:10.1093/infdis/jiab490
- Phillips S,Williams MA. Confronting our next national health disaster—long-haul Covid. N Engl J Med. 2021;385:577-9. [PMID: ] doi:10.1056/NEJMp2109285
- Prins JB,van der Meer JW,Bleijenberg G. Chronic fatigue syndrome. Lancet. 2006;367:346-55. [PMID: ]
- Carson PJ,Konewko P,Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis. 2006;43:723-30. [PMID: ]
- Lettinga KD,Verbon A,Nieuwkerk PT, et al. Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. Clin Infect Dis. 2002;35:11-7. [PMID: ]
- White PD,Thomas JM,Kangro HO, et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet. 2001;358:1946-54. [PMID: ]
- Wills AB,Spaulding AB,Adjemian J, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62:1546-51. [PMID: ] doi:10.1093/cid/ciw189
- Simon GE,VonKorff M,Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329-35. [PMID: ]
Source: PubMed